← Back to Search

Behavioral Intervention

PrEP-3D package for HIV Prevention (PrEP-3D RCT Trial)

N/A
Recruiting
Led By Susan Buchbinder, MD
Research Sponsored by Public Health Foundation Enterprises, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Assigned male at birth who reports sex with persons assigned male at birth
Owns a smartphone and has private access to the internet
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

PrEP-3D RCT Trial Summary

This trial will compare the effectiveness of the PrEP-3D app to standard of care for people starting and continuing PrEP, and adherence to PrEP.

Eligible Conditions
  • Pre-Exposure Prophylaxis
  • HIV Prevention
  • Risk Reduction
  • Medication Adherence

PrEP-3D RCT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are a male who has had sexual contact with other males.
Select...
You have a personal smartphone with access to the internet that you can use privately.

PrEP-3D RCT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Effectiveness of PREP-3D on PREP use

PrEP-3D RCT Trial Design

2Treatment groups
Experimental Treatment
Group I: PrEP-3DExperimental Treatment1 Intervention
Use of Alto Pharmacy, PrEP-3D mobile app and home laboratory testing.
Group II: Control ArmExperimental Treatment1 Intervention
Participants in the control arm will receive standard of care PREP navigation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Standard of Care
2017
Completed Phase 4
~4420

Find a Location

Who is running the clinical trial?

Public Health Foundation Enterprises, Inc.Lead Sponsor
13 Previous Clinical Trials
1,408 Total Patients Enrolled
5 Trials studying Pre-Exposure Prophylaxis
443 Patients Enrolled for Pre-Exposure Prophylaxis
San Francisco Department of Public HealthOTHER_GOV
35 Previous Clinical Trials
34,201 Total Patients Enrolled
5 Trials studying Pre-Exposure Prophylaxis
443 Patients Enrolled for Pre-Exposure Prophylaxis
Alto PharmacyUNKNOWN

Media Library

PrEP-3D package (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05474313 — N/A
Pre-Exposure Prophylaxis Research Study Groups: PrEP-3D, Control Arm
Pre-Exposure Prophylaxis Clinical Trial 2023: PrEP-3D package Highlights & Side Effects. Trial Name: NCT05474313 — N/A
PrEP-3D package (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05474313 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have been recruited for this research endeavor?

"Indeed, clinicaltrials.gov shows that this study is still recruiting volunteers; it was first made available on April 8th 2022 and the most recent update occurred on September 16th 2022. 150 people are required to be enrolled at 1 medical center."

Answered by AI

Is there still capacity for participants in this trial?

"Clinicaltrials.gov informs that this research study is recruiting volunteers, which was first advertised on April 8th and most recently updated September 16th of 2022."

Answered by AI
~51 spots leftby Mar 2025